 Roselinde Kaiser
Concepts (118)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Depressive Disorder, Major | 11 | 2025 | 374 | 2.760 |
Why?
| | Reward | 8 | 2025 | 256 | 1.680 |
Why?
| | Frontal Lobe | 3 | 2019 | 162 | 1.530 |
Why?
| | Mood Disorders | 2 | 2023 | 141 | 1.520 |
Why?
| | Cerebral Cortex | 4 | 2019 | 461 | 1.510 |
Why?
| | Depression | 7 | 2025 | 1483 | 1.460 |
Why?
| | Bipolar Disorder | 3 | 2024 | 276 | 1.280 |
Why?
| | Rest | 4 | 2026 | 128 | 1.270 |
Why?
| | Neural Pathways | 9 | 2025 | 308 | 1.220 |
Why?
| | Anhedonia | 3 | 2024 | 16 | 1.190 |
Why?
| | Affect | 4 | 2023 | 314 | 1.180 |
Why?
| | Connectome | 4 | 2024 | 93 | 1.060 |
Why?
| | Sertraline | 2 | 2022 | 29 | 0.910 |
Why?
| | Nerve Net | 3 | 2026 | 281 | 0.800 |
Why?
| | Magnetic Resonance Imaging | 19 | 2026 | 3709 | 0.800 |
Why?
| | Anticipation, Psychological | 1 | 2023 | 20 | 0.790 |
Why?
| | Dopamine | 4 | 2025 | 309 | 0.750 |
Why?
| | Depressive Disorder | 2 | 2017 | 394 | 0.750 |
Why?
| | Brain | 11 | 2026 | 2858 | 0.720 |
Why?
| | Amygdala | 1 | 2023 | 192 | 0.710 |
Why?
| | Nucleus Accumbens | 1 | 2023 | 151 | 0.700 |
Why?
| | Prefrontal Cortex | 3 | 2018 | 314 | 0.680 |
Why?
| | Rumination, Cognitive | 2 | 2025 | 11 | 0.660 |
Why?
| | Ventral Striatum | 2 | 2025 | 10 | 0.650 |
Why?
| | Dopamine Plasma Membrane Transport Proteins | 2 | 2025 | 60 | 0.630 |
Why?
| | Individuality | 2 | 2018 | 162 | 0.620 |
Why?
| | Parietal Lobe | 2 | 2018 | 60 | 0.590 |
Why?
| | Stress, Psychological | 2 | 2025 | 1128 | 0.550 |
Why?
| | Emotions | 3 | 2021 | 575 | 0.540 |
Why?
| | Young Adult | 15 | 2026 | 13673 | 0.520 |
Why?
| | Attention | 2 | 2026 | 454 | 0.520 |
Why?
| | Executive Function | 4 | 2025 | 457 | 0.470 |
Why?
| | Facial Recognition | 1 | 2015 | 34 | 0.460 |
Why?
| | Nonlinear Dynamics | 1 | 2015 | 92 | 0.450 |
Why?
| | Adolescent | 10 | 2025 | 22007 | 0.360 |
Why?
| | Impulsive Behavior | 2 | 2024 | 154 | 0.350 |
Why?
| | Adult | 19 | 2026 | 39177 | 0.340 |
Why?
| | Memory, Short-Term | 2 | 2023 | 267 | 0.290 |
Why?
| | Humans | 32 | 2026 | 141187 | 0.290 |
Why?
| | Functional Neuroimaging | 2 | 2019 | 60 | 0.260 |
Why?
| | Brain Mapping | 5 | 2022 | 532 | 0.250 |
Why?
| | Male | 19 | 2026 | 69783 | 0.240 |
Why?
| | Female | 21 | 2026 | 75515 | 0.240 |
Why?
| | Neuropsychological Tests | 2 | 2023 | 1085 | 0.240 |
Why?
| | Haloperidol | 1 | 2026 | 34 | 0.240 |
Why?
| | Methylphenidate | 1 | 2026 | 43 | 0.240 |
Why?
| | Stroop Test | 4 | 2022 | 25 | 0.240 |
Why?
| | Pessimism | 1 | 2025 | 10 | 0.230 |
Why?
| | Child Abuse, Sexual | 1 | 2025 | 83 | 0.220 |
Why?
| | Psychiatric Status Rating Scales | 2 | 2015 | 561 | 0.190 |
Why?
| | Positron-Emission Tomography | 2 | 2025 | 310 | 0.180 |
Why?
| | Corpus Striatum | 2 | 2025 | 177 | 0.160 |
Why?
| | Cues | 2 | 2020 | 322 | 0.160 |
Why?
| | Craving | 1 | 2020 | 38 | 0.160 |
Why?
| | Antidepressive Agents | 1 | 2022 | 254 | 0.160 |
Why?
| | Reaction Time | 3 | 2022 | 429 | 0.160 |
Why?
| | Antidepressive Agents, Second-Generation | 1 | 2019 | 50 | 0.150 |
Why?
| | Sex Offenses | 1 | 2022 | 200 | 0.150 |
Why?
| | Learning | 1 | 2023 | 437 | 0.150 |
Why?
| | Biomarkers | 2 | 2022 | 4174 | 0.150 |
Why?
| | Nicotine | 1 | 2021 | 350 | 0.140 |
Why?
| | Conditioning, Operant | 1 | 2018 | 103 | 0.140 |
Why?
| | Psychological Trauma | 1 | 2018 | 55 | 0.140 |
Why?
| | Psychomotor Performance | 2 | 2026 | 329 | 0.140 |
Why?
| | Smoking Cessation | 1 | 2021 | 440 | 0.130 |
Why?
| | Adult Survivors of Child Abuse | 1 | 2017 | 29 | 0.130 |
Why?
| | Sulpiride | 1 | 2016 | 5 | 0.130 |
Why?
| | Dopamine Antagonists | 1 | 2016 | 25 | 0.130 |
Why?
| | Dopaminergic Neurons | 1 | 2016 | 69 | 0.120 |
Why?
| | Sex Characteristics | 1 | 2021 | 788 | 0.120 |
Why?
| | Alcoholism | 1 | 2022 | 821 | 0.110 |
Why?
| | Synaptic Transmission | 1 | 2016 | 295 | 0.110 |
Why?
| | Machine Learning | 1 | 2019 | 553 | 0.100 |
Why?
| | Stress Disorders, Post-Traumatic | 2 | 2018 | 857 | 0.100 |
Why?
| | Photic Stimulation | 1 | 2014 | 255 | 0.100 |
Why?
| | Cognition Disorders | 1 | 2017 | 515 | 0.100 |
Why?
| | Mental Disorders | 1 | 2021 | 1120 | 0.100 |
Why?
| | Choice Behavior | 1 | 2013 | 172 | 0.090 |
Why?
| | Double-Blind Method | 3 | 2026 | 1983 | 0.090 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2015 | 772 | 0.090 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2892 | 0.080 |
Why?
| | Oxygen | 1 | 2015 | 993 | 0.080 |
Why?
| | Decision Making | 1 | 2017 | 961 | 0.080 |
Why?
| | Case-Control Studies | 1 | 2015 | 3588 | 0.070 |
Why?
| | Anxiety | 1 | 2013 | 1082 | 0.060 |
Why?
| | Ventral Tegmental Area | 1 | 2025 | 60 | 0.060 |
Why?
| | Students | 2 | 2025 | 645 | 0.060 |
Why?
| | Multimodal Imaging | 1 | 2025 | 120 | 0.050 |
Why?
| | Central Nervous System Stimulants | 1 | 2026 | 178 | 0.050 |
Why?
| | Middle Aged | 4 | 2024 | 34434 | 0.050 |
Why?
| | Neuroimaging | 1 | 2025 | 272 | 0.050 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2012 | 1123 | 0.050 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2012 | 1787 | 0.050 |
Why?
| | Models, Neurological | 1 | 2024 | 251 | 0.050 |
Why?
| | Gyrus Cinguli | 1 | 2022 | 94 | 0.050 |
Why?
| | Bupropion | 1 | 2020 | 46 | 0.040 |
Why?
| | Cross-Over Studies | 1 | 2021 | 578 | 0.040 |
Why?
| | Lung Neoplasms | 1 | 2012 | 2560 | 0.040 |
Why?
| | Psychometrics | 1 | 2021 | 739 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2025 | 2902 | 0.030 |
Why?
| | Avoidance Learning | 1 | 2016 | 74 | 0.030 |
Why?
| | Child | 2 | 2025 | 22308 | 0.030 |
Why?
| | Verbal Behavior | 1 | 2013 | 42 | 0.030 |
Why?
| | Cognition | 1 | 2021 | 1222 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2024 | 5636 | 0.020 |
Why?
| | Task Performance and Analysis | 1 | 2013 | 196 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2025 | 5929 | 0.020 |
Why?
| | Motivation | 1 | 2016 | 602 | 0.020 |
Why?
| | Carboplatin | 1 | 2012 | 146 | 0.020 |
Why?
| | Paclitaxel | 1 | 2012 | 237 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2012 | 771 | 0.020 |
Why?
| | Indoles | 1 | 2012 | 429 | 0.020 |
Why?
| | Neoplasm Staging | 1 | 2012 | 1398 | 0.020 |
Why?
| | Prospective Studies | 1 | 2020 | 7739 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2012 | 2064 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2020 | 11120 | 0.010 |
Why?
| | Cohort Studies | 1 | 2012 | 5799 | 0.010 |
Why?
| | Aged | 1 | 2012 | 24574 | 0.010 |
Why?
|
|
Kaiser's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|